Abbott Laboratories (ABT) rose 1.21% to $103.18, ending six consecutive days of losses after agreeing to pay the DOJ $385 million to resolve claims related to its 2022 baby formula recall. The company admitted no wrongdoing. Despite a 21% year-over-year decline and a Seeking Alpha 'Hold' rating due to valuation concerns, Wall Street maintains a consensus 'Buy' rating, citing renewed momentum in nutrition, diagnostics, and medical devices.
Abbott Laboratories jumps after six straight sessions of losses
Login to unlock442characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.